This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,
That is the opinion of Ron Emerson, RN, global healthcare lead at Zoom, as he looks ahead at what he believes will be some developments in healthcare in 2022. Virtual tools also facilitate access to medical training, as healthcare providers now can seek expert guidance from the other side of the globe at the touch of a button.
.” To drive impact with your AI initiatives, you must have a clear idea of what your organization is trying to achieve, what part of that goal is best suited for automation, and then select a solution with the training required to do what you are asking of them with a high degree of accuracy and reliability.
The new company aims to leverage its extensive data sets and technology to provide innovative solutions across various healthcare sectors, including lifesciences, provider, imaging, health plan, employer, and government health and human services. MarketScan University: Offers educational resources and training programs.
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drugdevelopment. This decline is happening at a time when the need for efficient drugdevelopment has never been greater. This happens because there are major gaps in the research needed to support clinical trials.
“We are excited to partner with Debiopharm and redefine the landscape of clinical development with AI,” said Livia Lifes, co-founder and CEO at Neuroute. The fund has already started its activity with two Seed investments, with two more to be announced soon.
Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast. “It Its mission is to improve patient outcomes, train the next generation of scientists and clinicians, and enhance the competitiveness of the UK lifesciences sector.
Cornerstone’s founders incubated the company in partnership with Initiate Studios, a new venture studio that co-creates companies at the intersection of healthcare, lifesciences and technology. Poor quality data leads to drugdevelopment being delayed, patients being misdiagnosed and inaccurate scientific conclusions.
Food and Drug Administration, biomedical and lifescience companies, nonprofits, patient-focused groups, and other organizations to transform the current model for developing new diagnostics and treatments. ALS is a progressive and ultimately fatal neurological disease with few treatment options and no cure yet.
Jesse Cugliotta, Global Industry GTM Lead, Healthcare & LifeSciences at Snowflake. Patient insight management will be a key strategic pillar: Lifescience organizations are more confident in the business value of insights management and are increasingly willing to commit the necessary technological resources to support this need.
Precision medicine will continue to evolve in 2024: In disease areas like oncology, we will start to see AI playing a larger role in target discovery and biomarker or patient subpopulation identification, the cornerstones to early precision drugdevelopment.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content